Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors’ reply-Reference-Cited by-同舟云学术

Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors’ reply

Published:2016-09-04 Issue:7 Volume:44 Page:772-773
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Narula N.¹,Reinisch W.¹²

Affiliation:

1. Division of Gastroenterology; Department of Medicine and Farncombe Family Digestive Health Research Institute; McMaster University; Hamilton ON Canada

2. Division of Gastroenterology and Hepatology; Department of Internal Medicine III; Medical University of Vienna; Vienna Austria

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13768/fullpdf

Reference4 articles.

1. Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location?;Srinivas;Aliment Pharmacol Ther,2016

2. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease;Narula;Aliment Pharmacol Ther,2016

3. Statistics in medicine - reporting of subgroup analyses in clinical trials;Wang;N Engl J Med,2007

4. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade: multicentre international study-supplementary report;BMJ,1977

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview;Medicina;2022-04-21